Literature DB >> 31928266

Effects of the recurrence pattern on patient survival following SABR for stage I lung cancer.

Elisabeth Weiss1, Xiaoyan Deng2, Nitai Mukhopadhyay2, Nuzhat Jan1.   

Abstract

Background: Information on the effect of the recurrence pattern on survival for stage I lung cancer following stereotactic ablative radiotherapy (SABR) is limited.Materials and
Methods: The recurrence pattern was analyzed for 100 consecutive stage I non-small-cell lung cancer patients treated with SABR using predominantly 12 Gy × 4. Recurrences were classified as local, regional lymph nodes and distant. Distant recurrences included recurrences in the lung and outside the chest. Single lung recurrences were named solitary, if no other location was involved. Kaplan-Meier survival estimates were calculated for different locations of recurrence. Clinical and dosimetrical factors affecting survival were also analyzed.
Results: Median follow-up was 32 months (3-123), median age 70 years (49-95). In total, 31 patients had recurrences after a median 21 months (4-60): 5 local; 10 regional; 8 distant outside the chest; 25 non-local lung recurrences, of which 15 were single - 10 of which solitary - and 10 multiple lung nodules. Patients with a solitary lung recurrence had longer survival compared to local or distant recurrences (p = .04 each), and compared to multiple lung nodules (p = .09). 3-year local recurrence-free survival was 92%, disease-free survival 69% and overall survival 59%. On multivariate analysis, disease-free survival was associated with statin use (p = .038) and tumor location (p = .035). Smoking history predicted overall survival (p < .0006).Conclusions: A total of 81% of recurrences involved the lungs. Patients with solitary lung recurrences/second primary lung cancers had the longest overall survival suggesting definitive treatment should be considered. The effects of statin use need to be explored further.

Entities:  

Mesh:

Year:  2020        PMID: 31928266      PMCID: PMC7060815          DOI: 10.1080/0284186X.2019.1711172

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  43 in total

1.  Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer.

Authors:  Sameer K Nath; Ajay P Sandhu; Daniel Kim; Anjali Bharne; Polly D Nobiensky; Joshua D Lawson; Mark Fuster; Lyudmila Bazhenova; William Y Song; Arno J Mundt
Journal:  Radiother Oncol       Date:  2011-03-21       Impact factor: 6.280

2.  A brief report on outcomes of stereotactic ablative radiotherapy for a second primary lung cancer: evidence in support of routine CT surveillance.

Authors:  Gwendolyn H M J Griffioen; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

3.  Dose-response in stereotactic irradiation of lung tumors.

Authors:  Joern Wulf; Kurt Baier; Gerd Mueller; Michael P Flentje
Journal:  Radiother Oncol       Date:  2005-10-04       Impact factor: 6.280

4.  A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.

Authors:  Inga Siiner Grills; Andrew J Hope; Matthias Guckenberger; Larry L Kestin; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Juergen Wilbert; Ying Xiao; Jose Belderbos
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

5.  Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.

Authors:  Kevin L Stephans; Neil M Woody; Chandana A Reddy; Matthew Varley; Anthony Magnelli; Tingliang Zhuang; Peng Qi; Gregory M M Videtic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-10-28       Impact factor: 7.038

6.  The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.

Authors:  Zishan Allibhai; Mojgan Taremi; Andrea Bezjak; Anthony Brade; Andrew J Hope; Alexander Sun; B C John Cho
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-24       Impact factor: 7.038

7.  Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer.

Authors:  Yuichiro Tsurugai; Takuyo Kozuka; Naoki Ishizuka; Masahiko Oguchi
Journal:  Lung Cancer       Date:  2015-12-17       Impact factor: 5.705

8.  Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population.

Authors:  Carol H Christensen; Brian Rostron; Candace Cosgrove; Sean F Altekruse; Anne M Hartman; James T Gibson; Benjamin Apelberg; Maki Inoue-Choi; Neal D Freedman
Journal:  JAMA Intern Med       Date:  2018-04-01       Impact factor: 21.873

9.  Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study.

Authors:  Min-Chun Chuang; Yao-Hsu Yang; Ying-Huang Tsai; Meng-Jer Hsieh; Yu-Ching Lin; Chin-Kuo Lin; Pau-Chung Chen; Tsung-Ming Yang
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

10.  Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair.

Authors:  Yu-An Chen; Hua-Wei Shih; Yi-Chun Lin; Hui-Ying Hsu; Tsu-Fang Wu; Chen-Han Tsai; Chia-Lin Wu; Hui-Yu Wu; Jer-Tsong Hsieh; Chih-Hsin Tang; Chih-Ho Lai
Journal:  Front Pharmacol       Date:  2018-06-13       Impact factor: 5.810

View more
  2 in total

1.  Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.

Authors:  Xiaoli Zheng; Yanan Sun; Ke Ye; Chengcheng Fan; Xiaohui Wang; Yang Yang; Ruidi Jiao; Hong Ge
Journal:  Thorac Cancer       Date:  2021-02-02       Impact factor: 3.500

Review 2.  Relationship between Dose Prescription Methods and Local Control Rate in Stereotactic Body Radiotherapy for Early Stage Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.

Authors:  Takahisa Eriguchi; Atsuya Takeda; Takafumi Nemoto; Yuichiro Tsurugai; Naoko Sanuki; Yudai Tateishi; Yuichi Kibe; Takeshi Akiba; Mari Inoue; Kengo Nagashima; Nobuyuki Horita
Journal:  Cancers (Basel)       Date:  2022-08-05       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.